The ECMO to Rescue Lung Injury in Severe Acute Respiratory Distress Syndrome (EOLIA) trial showed a trend towards improved survival and a significant reduction in the need for vasopressors, dialysis and proning in ECMO‐enrolled subjects with severe acute respiratory distress syndrome. 50 Follow‐up meta‐analysis and Bayesian analyses supported the interpretation that ECMO offers benefit for severely ill acute respiratory distress syndrome patients. 51 , 52 Future studies will be required to assess whether the oxygenators capture amyloid and tau variants from the circulation and confer some benefit, and whether circulating tau represents a prognostic biomarker for end organ dysfunction.
1
—
—